此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of the Subdermal Implant "Ultracol"

2026年5月25日 更新者:Estelab Clinic

A Single-center Clinical Study of the Efficacy and Safety of the Medical Device "Intradermal Implant, Sterile ULTRACOL Based on Polydioxanone (ULTRA V Co., Ltd., Korea) in the Correction of Skin Contour Defects.

Study of the effectiveness of the medical device "Intradermal implant, sterile ULTRACOL based on polydioxanone (ULTRA V Co., Ltd., Korea) in the correction of skin contour defects.

研究概览

详细说明

The investigational product is composed of a mixture of polydioxanone and sodium carboxymethylcellulose. The polydioxanone content is as follows: Ultracol 200: 150 mg ±10%, Ultracol 100: 75 mg ±10%. The key difference from the closest analogs (AestheFill® V200, Sculptra™, Ellagen PLLA+CMC 1000 mg) is the presence of polydioxanone in the investigational product.

Thus, the analyzed analogues are not fully interchangeable medical products. The combined composition of Ultracol has not been studied properly. Therefore, during the clinical study, it is necessary to check the safety and effectiveness of a medical product with a combined composition - polydioxanone and sodium carboxymethylcellulose.

研究类型

介入性

注册 (实际的)

23

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Russia
      • Moscow、Russia、俄罗斯、119034
        • Estelab CLinic

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • The subject has indications for use according to the manufacturer instructions for the device.
  • The subject is at least 18 years old at the time of signing the informed consent.
  • The subject expresses willingness and ability to follow the requirements of the study protocol.
  • The subject has no contraindications described in the device instructions for use.

Exclusion Criteria:

  • The subject has at least one contraindication described in the device instructions for use, based on initial examination, laboratory tests and medical history.
  • Women of reproductive age: pregnancy, planning pregnancy during the study period, or breastfeeding.
  • Use of another product for the same indication during the clinical study.
  • Participation in another clinical study.
  • Pre-existing health problems that may compromise compliance with the study protocol.
  • Patients prone to excessive scarring.
  • Patients undergoing chemotherapy.
  • Patients previously treated with intradermal fillers in the planned injection zone with persistent effect.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Experimental Group
ULTRACOL Intradermal Implant (Polydioxanone-based). All 23 adult subjects (22 female, 3 male; mean age 51.1, range 37-70) received intradermal injections of ULTRACOL using linear-retrograde technique into the lower dermis or hypodermis. ULTRACOL 100 (100 mg/vial, reconstituted in 1 mL water for injection) used in all 23 patients; ULTRACOL 200 (200 mg/vial, reconstituted in 2 mL water for injection) used in 20 patients. Mean 1.87 injections per patient. Maximum dose: 3 mL per procedure. Treatment zones: nasolabial folds, cheeks, zygomatic area, perioral/periauricular regions, facial oval. Follow-up: Day 30, 60, 160.
Lyophilized intradermal implant based on polydioxanone (PDO) and sodium carboxymethylcellulose (Na-CMC). ULTRACOL 100: 100 mg/vial (75 mg PDO), reconstituted in 1 mL water for injection. ULTRACOL 200: 200 mg/vial (150 mg PDO), reconstituted in 2 mL water for injection. Administered intradermally using linear-retrograde technique. Maximum dose: 3 mL per procedure. Mean 1.87 injections per subject. Manufactured by ULTRA V Co., Ltd., Republic of Korea. Class III medical device. Biostimulating mechanism: PDO hydrolysis stimulates neocollagenesis.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Wrinkle Severity Rating Scale (WSRS) Score
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
Validated 5-point scale (1 = no wrinkles, 5 = extreme wrinkles) assessed by the investigator. A reduction of 1 or more points compared to baseline is considered clinically significant. Units: Score on a scale (1-5).
Baseline, Day 30, Day 60, Day 160 after first injection

次要结果测量

结果测量
措施说明
大体时间
Change in Baker Ptosis Classification
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
4-grade classification of facial soft tissue ptosis assessed by the investigator (Grade I = minimal, Grade IV = severe). Unit: Score on a scale (I-IV).
Baseline, Day 30, Day 60, Day 160 after first injection
Global Aesthetic Improvement Scale (GAIS) - Investigator Assessment
大体时间:Day 30, Day 60, Day 160 after first injection
5-point Global Aesthetic Improvement Scale (0 = worse, 1 = no change, 2 = improved, 3 = much improved, 4 = very much improved) assessed by the investigator. Unit: Score on a scale (0-4).
Day 30, Day 60, Day 160 after first injection
Global Aesthetic Improvement Scale (GAIS) - Subject Self-Assessment
大体时间:Day 30, Day 60, Day 160 after first injection
5-point Global Aesthetic Improvement Scale (0 = worse, 4 = very much improved) assessed by the subject. Unit: Score on a scale (0-4).
Day 30, Day 60, Day 160 after first injection
Change in Perceived Age (Subject Self-Assessment)
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
Subject self-assessment of perceived age before and after treatment. A reduction of at least 1 year is considered clinically meaningful. Unit: Years.
Baseline, Day 30, Day 60, Day 160 after first injection
Change in Skin Parameters by Multi-Parametric Ultrasound
大体时间:Baseline and Day 160 after first injection
Multi-parametric facial skin ultrasound assessing: epidermis thickness (mm), papillary dermis thickness (mm), reticular dermis thickness (mm), subcutaneous fat thickness (mm), vascularization index (%), dermis stiffness via compression elastography (kPa). Unit: Combined imaging parameters reported per individual measurement (mm / % / kPa).
Baseline and Day 160 after first injection
Change in Lemperle Scale (Nasolabial Fold Depth)
大体时间:Baseline, Day 30, Day 60, Day 160 after first injection
5-point Lemperle scale for assessment of nasolabial fold depth (0 = no wrinkle, 5 = very deep wrinkle), assessed by the investigator. Unit: Score on a scale (0-5).
Baseline, Day 30, Day 60, Day 160 after first injection
Number of Participants with Adverse Events (AEs) and Adverse Device Effects (ADEs)
大体时间:From first injection through Day 160 (160-day follow-up)
Frequency and severity of adverse events (AEs) and adverse device effects (ADEs), assessed by the investigator and recorded throughout the study. Unit: Number of Participants.
From first injection through Day 160 (160-day follow-up)
Number of Participants with Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs)
大体时间:From first injection through Day 160 (160-day follow-up)
Frequency of serious adverse events (SAEs) and serious adverse device effects (SADEs), assessed by the investigator and recorded throughout the study. Unit: Number of Participants.
From first injection through Day 160 (160-day follow-up)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月16日

初级完成 (实际的)

2025年3月12日

研究完成 (实际的)

2025年4月10日

研究注册日期

首次提交

2024年10月23日

首先提交符合 QC 标准的

2026年5月25日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月25日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅